Recently, Sogol Mostoufi-Moab, MD, MSCE, a dual-certified pediatric oncologist and endocrinologist with CHOP’s Endocrine Late Effects after Cancer Therapy (ELECT) Program, was featured as an expert in a HemOnc Today article about the consequences of more and more cancer survivors living full life spans. The article addressed the fact that children undergoing cancer treatment are a unique population and have the longest duration of survivorship ahead of them. Dr. Mostoufi-Moab discussed the importance of considering the risk of harm a treatment might cause a child in the future, and the importance of factors such as age and tumor location. When considering endocrine late effects, a 4-year-old patient poses different concerns than a 16-year-old patient. “Understanding these factors is critical to recognize and anticipate the spectrum of late effects that can present over years,” Dr. Mostoufi-Moab said.
The article also addressed the looming shortage of oncologists to care for survivors, the distinction between chronic effects and late effects of treatment, and other common late effects, such as cardiovascular diseases.